Pentixapharm presents first-in-human data on Lu177-PentixaTher for Muscle-Invasive Bladder Cancer at ASCO-GU 2025, showing potential for bladder preservation and targeted treatment ...

ConferenceFirst-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with Pentixapharm’s Lu177-PentixaTher to be Presented at ASCO-GU 2025 13.02.2025 / 14:10 CET/CESTThe issuer is ...

Announcing a new publication for Acta Materia Medica journal. Single-cell RNA sequencing (scRNA-seq) data from published datasets were obtained to investigate the expression and dysregulation of ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

BOSTON—X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a biotech company with a market capitalization of $84 million, saw its Chief ...

EMA validates X4 Pharma’s marketing authorization application for mavorixafor to treat WHIM syndrome: Boston Monday, January 27, 2025, 11:00 Hrs [IST] X4 Pharmaceuticals, a comp ...

ALX40-4C NPS Allelix Terminated (Phase I/II) HIV No apparent effect was observed on viral load AMD3100 AnorMED Terminated (Phase I/II) HIV Little effect was observed on viral load AMD3100 ...

We look forward to working alongside the EMA as they assess our application.” Mavorixafor is a small-molecule antagonist of the CXCR4 receptor being developed as a once-daily oral therapy for people ...

Mavorixafor is a small-molecule antagonist of the CXCR4 receptor being developed as a once-daily oral therapy for people with rare primary immunodeficiencies, including WHIM syndrome. The global ...